I hope AZN still has enough money put aside to partner with MNKD.(Remember Gloria?)

-------------------------------------------------------------------------------------------------------

Title: Amylin Bows Out Gracefully

The long drama around the Amylin Pharmaceuticals (AMLN) looks like it has reached its end - Bristol-Myers Squibb (BMY) announced the acquisition of Amylin late Friday night in a deal that will pay Amylin shareholders $31 per share in cash. While some sources have reported the size of the deal as $5.3 billion, it's actually larger than that (about $7 billion) as Bristol-Myers will also be taking on over half a billion in Amylin debt and over $1 billion in financial obligations to Lilly (LLY).

Bristol-Myers is also bringing a partner into this deal. While it technically won't take place until the Bristol-Amylin merger closes, AstraZeneca (AZN) will be buying in as part of the existing diabetes drug partnership between the two companies. For $3.4 billion, AstraZeneca will be getting a 50% interest in Amylin's products and the option to chip in another $135 million for the right to equal say in the management and strategic planning of the collaboration.

Read the rest of this article at

http://seekingalpha.com/article/694331-amylin-bows-out-gracefully?source=email_authors_alerts&ifp=0

Date Originally Published: July 1st, 2012

Author: Stephen Simpson